Latest Lakewood-Amedex Biotherapeutics News & Updates

See the latest news and media coverage for Lakewood Amedex. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Lakewood-Amedex Biotherapeutics (Lakewood Amedex)

Antimicrobial drug developer

lakewoodamedex.com
Headquarters
University Park, United States
Company type
Public company
Number of employees
5–10

Last updated

Latest news about Lakewood-Amedex Biotherapeutics (Lakewood Amedex)

In short: Lakewood Amedex expanded its intellectual property and advanced its lead antimicrobial candidate Nu-3 through new clinical partnerships.

Company announcements

Lakewood Amedex

Lakewood-Amedex expands global IP portfolio for lead candidate Nu-3

The portfolio now includes 71 granted and 28 pending patents covering composition of matter, formulation, and use.

Unlock all announcements with a

Media coverage

Barron's

Lakewood-Amedex Biotherapeutics Inc.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least...

Markets Insider

Lakewood-Amedex Prepares To Launch A Phase 2 cDFU Clinical Trial for Its Nu-3 Antimicrobial In The Bahamas

ANNOUNCES COLLABORATION WITH NASSAU BASED SURGICAL GROUP, FOOT AND ANKLE INTERNATIONAL (BAHAMAS) SARASOTA, Florida, Jan. 17, 2019 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of...

Unlock all articles with a

Never miss news about Lakewood Amedex

Track Lakewood Amedex and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.